Schrödinger, Inc.

SDGR ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-103.3M $-187.1M $40.7M $-149.2M $-100.4M $-24.5M $-24.6M
Depreciation & Amortization $6.0M $6.2M $5.6M $4.3M $2.8M $3.7M $3.6M
Depreciation $6.0M $6.2M $5.0M $3.8M $2.8M $3.7M $3.6M
Amortization — — $587.0K $513.0K $0 — —
Stock-Based Compensation $43.0M $49.9M $47.8M $39.6M $26.5M $10.5M $2.2M
Net Cash from Operating Activities $13.9M $-157.4M $-136.7M $-119.7M $-70.7M $16.8M $-26.1M
Investing Activities
Capital Expenditures $1.4M $7.3M $13.4M $8.0M $7.2M $2.5M $1.8M
Business Acquisitions — $0 $0 $6.4M $0 $0 —
Net Cash from Investing Activities $57.9M $148.8M $193.0M $90.0M $-16.8M $-381.7M $-53.9M
Financing Activities
Dividends Paid — — — — — — —
Stock Repurchases — — — — — — —
Net Cash from Financing Activities $2.9M $10.1M $9.0M $2.1M $8.0M $541.3M $28.7M
Net Change in Cash $74.7M $1.6M $65.3M $-27.6M $-79.5M $176.3M —
Free Cash Flow $12.5M $-164.7M $-150.1M $-127.7M $-77.8M $14.2M $-27.9M